Lantern Pharma has won a trio of rare-pediatric-disease designations from the Food and Drug Administration for its investigational drug candidate LP-184 in multiple ultra-rare children's cancers.
Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma. Lantern's investigational drug candidate, LP-184, has ...
An Upstate mom shares the uphill battle to recovery from her daughter's cancer and is grateful for where they are now. Kylie Jeter, 3, is an energetic little girl, but just a few years ago, it was a ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...